所有图片(1)
About This Item
经验公式（希尔记法）:
C15H12N2O
CAS号:
分子量:
236.27
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
推荐产品
等级
pharmaceutical primary standard
API类
carbamazepine
制造商/商品名称
USP
mp
191-192 °C (lit.)
应用
pharmaceutical (small molecule)
包装形式
neat
SMILES字符串
NC(=O)N1c2ccccc2C=Cc3ccccc13
InChI
1S/C15H12N2O/c16-15(18)17-13-7-3-1-5-11(13)9-10-12-6-2-4-8-14(12)17/h1-10H,(H2,16,18)
InChI key
FFGPTBGBLSHEPO-UHFFFAOYSA-N
基因信息
human ... SCN10A(6336) , SCN11A(11280) , SCN1A(6323) , SCN2A(6326) , SCN3A(6328) , SCN4A(6329) , SCN5A(6331) , SCN7A(6332) , SCN8A(6334) , SCN9A(6335)
正在寻找类似产品? 访问 产品对比指南
相关类别
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Carbamazepine USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Carbamazepine Extended-Release Tablets
- Carbamazepine Oral Suspension
- Carbamazepine Tablets
- Oxcarbazepine
- Oxcarbazepine Oral Suspension
- Oxcarbazepine Tablets
生化/生理作用
抗惊厥药；GABAA受体苯二氮卓调节位点的配体。钠离子通道抑制剂。
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
相关产品
产品编号
说明
价格
警示用语：
Danger
危险分类
Acute Tox. 4 Oral - Repr. 1A - Resp. Sens. 1 - Skin Sens. 1A - STOT SE 3
靶器官
Central nervous system
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 2
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Ursula Amstutz et al.
Epilepsia, 55(4), 496-506 (2014-03-07)
To systematically review evidence on genetic risk factors for carbamazepine (CBZ)-induced hypersensitivity reactions (HSRs) and provide practice recommendations addressing the key questions: (1) Should genetic testing for HLA-B*15:02 and HLA-A*31:01 be performed in patients with an indication for CBZ therapy
Anna Jurado et al.
Chemosphere, 115, 47-53 (2014-02-25)
This paper deals with urban groundwater contaminated with carbamazepine (CBZ) and five of its human metabolites in Barcelona. Groundwater samples were accordingly collected in the aquifers of Poble Sec and Besòs River Delta. Higher concentrations and more compounds were found
Wimonchat Tangamornsuksan et al.
JAMA dermatology, 149(9), 1025-1032 (2013-07-26)
The US Food and Drug Administration recommends screening for the HLA-B*1502 allele before initiation of carbamazepine therapy in patients of Asian ancestry, but there remains unclear evidence of a relationship between HLA-B*1502 and Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis
Philip J Wiffen et al.
The Cochrane database of systematic reviews, (1)(1), CD005451-CD005451 (2011-01-21)
Carbamazepine is used to treat chronic neuropathic pain. Evaluation of analgesic efficacy and adverse effects of carbamazepine for acute and chronic pain management (except headaches). Randomised controlled trials (RCTs) of carbamazepine in acute, chronic or cancer pain were identified, searching
Janneke Jentink et al.
BMJ (Clinical research ed.), 341, c6581-c6581 (2010-12-04)
To identify specific major congenital malformations associated with use of carbamazepine in the first trimester of pregnancy. A review of all published cohort studies to identify key indications and a population based case-control study to test these indications. Review of
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门